AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06217887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide Group
Description: Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study NCT03941613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEEG guided RF-TC
Description: SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
Study NCT03941613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy
Description: classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
Study NCT04567693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early spaced-out appointments
Description: Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
Study NCT06623175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: See arm description
Study NCT04483375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: recombinant humanized anti-SARS-CoV-2 monoclonal antibody
Study NCT04483375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02039518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2，d1，d8，Q3W
Study NCT02039518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: observation group
Description: observation group
Study NCT04483817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
Study NCT04483817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tibial nerve stimulation
Description: Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
Study NCT02478034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fludrocortisone
Description: effects of fludrocortisone on cognition compared to placebo
Study NCT02478034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: effects of fludrocortisone on cognition compared to placebo
Study NCT01905553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt
Study NCT03696108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID
Study NCT00744315 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini-thoracotomy for intramyocardial injection of VEGF165
Description: Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
Study NCT03696108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
Study NCT00723255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00723255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT02006797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reconciliation
Description: medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
Study NCT03946449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection (TAK-999, ARO-AAT)
Description: solution for subcutaneous (sc) injection
Study NCT01687465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser trabeculoplasty
Description: With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
Study NCT01687465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
Study NCT01077609 — intervention group
Intervention type: DRUG
Intervention: Intermittent, sub-chronic and chronic Flixonase use
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Study NCT01077609 — intervention group
Intervention type: DRUG
Intervention: Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Study NCT02032862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sage extract, 3400 mg , DER 1:17
Study NCT03992573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CGF application
Description: CGF application into post-operative soft tissue and bone defects
Study NCT01245543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC480IV
Description: AC480IV will be administered as an infusion using a dose escalation design.
Study NCT01245543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
Study NCT04654754 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
Study NCT04654754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
Study NCT04654754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
Study NCT02784613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
Study NCT03886779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: 0.7 MG/ML \[Prolensa\]
Study NCT03886779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: 3 MG/ML \[Ilevro\]
Study NCT05033730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation
Description: Mechanically ventilated using Flow Controlled Ventilation (FCV)
Study NCT00638443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
Study NCT00634985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eletriptan
Description: 40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
Study NCT01821430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
Study NCT01821430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will follow the same titration as the pregabalin group
Study NCT02384967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
Study NCT00749385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400
Description: A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
Study NCT00749385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC naproxen plus EC esomeprazole
Description: Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
Study NCT00749385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC naproxen
Description: Enteric-coated naproxen tablet (500mg)
Study NCT00749385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC esomeprazole
Description: Enteric-coated esomeprazole capsule (20mg)
Study NCT00818103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 40mg p.o. qn for 2 years
Study NCT00818103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-interferon
Description: β-interferon 50ug i.m. qod for 2 years
Study NCT00818103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: EPO 10000U i.h. bid for 5 days
Study NCT02292810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle exercise
Description: For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
Study NCT02292810 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory muscle exercise placebo
Description: For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
Study NCT00808301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free products
Description: Gluten-free bakery products containing oatmeal.
Study NCT00638443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
Study NCT03492398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Study NCT05896462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% povidone iodine
Description: The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
Study NCT04057131 — intervention group
Intervention type: DRUG
Intervention: Firazyr
Description: Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
Study NCT02012842 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non surgical periodontal treatment
Description: Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
Study NCT02012842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal treatment
Description: Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
Study NCT04589546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Description: Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
Study NCT04589546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
Study NCT00981045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
Study NCT00981045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose (Venofer)
Description: 5 doses of 200 mg for a total cumulative dose of 1000 mg
Study NCT03274141 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT00431028 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: slow delivery ciprofloxacin + triamcinolone
Description: 2 mg ciprofloxacin + 25mg triamcinolone
Study NCT00220324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minisiston (SH D00342A)
Description: Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
Study NCT04054973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 6000mg of L-arginine daily for 14 days
Study NCT04024371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-rating Questionnaires
Description: * Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)
Study NCT04024371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measures of Reward processing/reinforcement learning
Description: * Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)
Study NCT04054973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: 800mg of Kuvan daily for 14 days
Study NCT03258840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA Supplement
Description: EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
Study NCT03258840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA Placebo
Description: EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
Study NCT02898727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local Therapy
Description: Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions.
Study NCT04024371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Additional Schizophrenia-specific Questionnaires and Interviews
Description: * Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)
Study NCT02413554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Description: acetylcholine esterase inhibitor
Study NCT03657524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: Speckle tracking echocardiography
Study NCT03657524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: Speckle tracking echocardiography
Study NCT00595517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Description: Esomeprazole 20 mg once daily
Study NCT03701841 — intervention group
Intervention type: DRUG
Intervention: PEG-rhG-CSF
Description: All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
Study NCT04231877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04231877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET scan
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04231877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT02630225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention
Description: The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers.